As shown in Figure 5A, patients harboring IDH mutation expressed high TP53I13 levels (red and green) and had poor survival outcomes, further confirming that TP53I13 could be a potential prognostic biomarker for gliomas. This evidence concerns the gene IDH1 and glioma.